Autolus Therapeutics PLC (AUTL)

Autolus Therapeutics Receives Prix Galien UK Award

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...

Form 8-K - Current report

Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of...

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...

Form 8-K - Current report

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Initiative focused on driving gross profit margin and path to profitability for the ALL businessCompany will...

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...

Form 8-K - Current report